A stochastic framework for estimation of summary measures in cost–effectiveness analyses

References

• Beck JR, Pauker SG. The Markov process in medical prognosis. Med. Dec. Making3(4), 419–458 (1983).
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov-models in medical decision-making – a practical guide. Med. Dec. Making13(4), 322–338 (1993).
   PubMed Web of Science ®Google Scholar
• Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis 5. Working with Markov processes. Med. Dec. Making17(2), 152–159 (1997).
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics13(4), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• Perez-Ocon R, Ruiz-Castro JE, Gamiz-Perez ML. Markov models with lognormal transition rates in the analysis of survival times. Test9(2), 353–370 (2000).
   Google Scholar
• Perez-Ocon R, Ruiz-Castro JE, Gamiz-Perez ML. Non-homogeneous Markov models in the analysis of survival after breast cancer. J. R. Stat. Soc.50, 111–124 (2001).
   Google Scholar
• Perez-Ocon R, Ruiz-Castro JE, Gamiz-Perez ML. A piecewise Markov process for analysing survival from breast cancer in different risk groups. Stat. Med.20(1), 109–122 (2001).
   PubMedGoogle Scholar
• Wanek LA, Elashoff RM, Goradia TM, Morton DL, Cochran AJ. Application of multistage Markov modeling to malignant-melanoma progression. Cancer73(2), 336–343 (1994).
   Google Scholar
• Wanek LA, Goradia TM, Elashoff RM, Morton DL. Multistage Markov analysis of progressive disease applied to melanoma. Biomet. J.35(8), 967–983 (1993).
   Web of Science ®Google Scholar
• Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural-history of prostate-cancer. J. Clin. Epidemiol.47(1), 3–21 (1994).
   PubMed Web of Science ®Google Scholar
• Thompson S. Statistical issues in cost–effectiveness analyses. Stat. Methods Med. Res.11(6), 453–454 (2002).
   Google Scholar
• Levy AR, Briggs AH, Demers C, O’Brien BJ. Cost–effectiveness of β-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am. Heart J.142(3), 537–543 (2001).
   PubMed Web of Science ®Google Scholar
• Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models Based on Counting Processes. Springer-Verlag, New York, USA (1993).
   Google Scholar
• Klein JP, Szydlo RM, Craddock C, Goldman JM. Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. Stat. Med.19(21), 3005–3016 (2000).
   PubMed Web of Science ®Google Scholar
• Hougaard P. Analysis of Multivariate Survival Data. Springer-Verlag, New York, USA (2000).
   Google Scholar
• Andersen PK, Esbjerg S, Sorensen TIA. Multi-state models for bleeding episodes and mortality in liver cirrhosis. Stat. Med.19(4), 587–599 (2000).
   PubMed Web of Science ®Google Scholar
• Klein JP, Shu YY. Multi-state models for bone marrow transplantation studies. Stat. Methods Med. Res.11(2), 117–139 (2002).
   PubMed Web of Science ®Google Scholar
• Hunink M, Glasziou P, Siegel J et al. Decision Making in Health and Medicine. Cambridge University Press, Cambridge, UK (2001).
   Google Scholar
• Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, Chapman & Hall/CRC (2002).
   Google Scholar
• Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Isacson DGL, Borgquist L. The relationship between health-state utilities and the SF-12 in a general population. Med. Dec. Making19(2), 128–140 (1999).
   PubMed Web of Science ®Google Scholar
• Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clinic. Epidemiol.51(11), 1115–1128 (1998).
   PubMed Web of Science ®Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost–effectiveness analysis. Med. Dec. Making18(2), S68–S80 (1998).
   PubMed Web of Science ®Google Scholar
• Gardiner JC, Sirbu CM, Rahbar MH. Update on statistical power and sample size assessments for cost–effectiveness studies. Expert Rev. Pharmacoeconomics Outcomes Res.4(1), 89–98 (2004).
   PubMedGoogle Scholar
• Gardiner JC, Huebner M, Jetton J, Bradley CJ. On parametric confidence intervals for the cost–effectiveness ratio. Biomet. J.43(3), 283–296 (2001).
   Web of Science ®Google Scholar
• Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost–effectiveness analyses. Expert Rev. Pharmacoeconomics Outcomes Res.1(1), 25–36 (2001).
   PubMedGoogle Scholar
• Briggs AH. A Bayesian approach to stochastic cost–effectiveness analysis. Health Econ.8(3), 257–261 (1999).
   PubMed Web of Science ®Google Scholar
• O’Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost–effectiveness ratio. Pharmacoeconomics17(4), 339–349 (2000).
   PubMed Web of Science ®Google Scholar
• O’Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat. Med.20(5), 733–753 (2001).
   PubMed Web of Science ®Google Scholar
• Van Hout BA, Al MJ, Gordon GS, Ruten FFH. Costs, effects and C/E-ratios alongside a clinical-trial. Health Econ.3(5), 309–319 (1994).
   PubMed Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ.10(8), 779–787 (2001).
   PubMed Web of Science ®Google Scholar
• Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ.9(7), 623–630 (2000).
   PubMed Web of Science ®Google Scholar
• Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions. Health Econ.13(5), 405–415 (2004).
   PubMed Web of Science ®Google Scholar
• Chen PL, Sen PK. Quality-adjusted survival estimation with periodic observations: a multistate survival analysis approach. Comm. Stat.33(6), 1327–1339 (2004).
   Google Scholar
• Shen LZ, Pulkstenis E, Hoseyni M. Estimation of mean quality adjusted survival time. Stat. Med.18(12), 1541–1554 (1999).
   PubMed Web of Science ®Google Scholar
• Huang YJ, Louis TA. Expressing estimators of expected quality adjusted survival as functions of Nelson-Aalen estimators. Lifetime Data Analysis5(3), 199–212 (1999).
   PubMed Web of Science ®Google Scholar
• Strawderman RL. Estimating the mean of an increasing stochastic process at a censored stopping time. J. Am. Stat. Assoc.95(452), 1192–1208 (2000).
   Web of Science ®Google Scholar
• Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics53(2), 419–434 (1997).
   PubMed Web of Science ®Google Scholar
• Gardiner JC, Luo Z, Bradley CJ, Polverejan E, Holmes-Rovner M, Rovner D. Longitudinal assessment of cost in health care interventions. Health Services Outcomes Res. Methodology3, 149–168 (2002).
   Google Scholar
• Andersen PK, Keiding N. Multi-state models for event history analysis. Stat. Methods Med. Res.11(2), 91–115 (2002).
   PubMed Web of Science ®Google Scholar
• Lin DY. Regression analysis of incomplete medical cost data. Stat. Med.22(7), 1181–1200 (2003).
   PubMed Web of Science ®Google Scholar
• Jain AK, Strawderman RL. Flexible hazard regression modeling for medical cost data. Biostatistics3(1), 101–118 (2002).
   Google Scholar
• Baser O, Gardiner JC, Bradley CJ, Given CW. Estimation from censored medical cost data. Biomet. J.46(3), 351–363 (2004).
   Web of Science ®Google Scholar
• Huang YJ. Calibration regression of censored lifetime medical cost. J. Am. Stat. Assoc.97(457), 318–327 (2002).
   Web of Science ®Google Scholar
• Bang H, Tsiatis AA. Median regression with censored cost data. Biometrics58(3), 643–649 (2002).
   PubMed Web of Science ®Google Scholar
• Lin DY. Linear regression of censored medical costs. Biostatistics1, 35–47 (2000).
   PubMedGoogle Scholar
• Baser O, Gardiner JC, Bradley CJ, Yuce H, Given CW. Longitudinal analysis of censored medical costs data. Health Econ.15(5), 513– 525 (2006).
   PubMed Web of Science ®Google Scholar
• Gardiner JC, Luo Z, Bradley CJ, Sirbu CM, Given CW. A dynamic model for estimating changes in health status and costs. Stat. Med. (2006) (In Press).
   Google Scholar
• Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat. Med.24(1), 131–145 (2005).
   Google Scholar
• Banks J. Output analysis capabilities of simulation software. Simulation66(1), 23–30 (1996).
   Google Scholar
• Banks J, Carson JS, Nelson BL. Discrete-Event System Simulation. 2nd Edition. Upper Saddle River, NJ, Prentice-Hall (1996).
   Google Scholar
• Jun JB, Jacobson SH, Swisher JR. Application of discrete-event simulation in health care clinics: a survey. J. Operational Res. Soc.50(2), 109–123 (1999).
   Web of Science ®Google Scholar
• Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost–effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Stat. Med.18(23), 3245–3262 (1999).
   PubMed Web of Science ®Google Scholar
• Indurkhya A, Gardiner JC, Luo ZH. The effect of outliers on confidence interval procedures for cost–effectiveness ratios. Stat. Med.20(9–10), 1469–1477 (2001).
   Google Scholar
• Gardiner JC, Indurkhya A, Luo Z. The performance of estimation procedures for cost–effectiveness ratios. In: Advances on Methodological and Applied Aspects of Probability and Statistics. Balakrishnan N (Ed.). Taylor & Francis, New York, USA 547–559 (2002).
   Google Scholar
• Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BEK. Health status and hypertension: a population-based study. J. Clin. Epidemiol.49(11), 1239–1245 (1996).
   PubMed Web of Science ®Google Scholar
• Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: Estimation of the Health Utility Index (HUI2) from the SF-36. Med. Dec. Making21(2), 105–112 (2001).
   PubMed Web of Science ®Google Scholar
• Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression-models for repeated outcomes in the presence of missing data. J. Am. Stat. Assoc.90(429), 106–121 (1995).
   Web of Science ®Google Scholar
• Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika87(2), 329–343 (2000).
   Web of Science ®Google Scholar